Compare Icl Group Ltd (ICL) vs Iovance Biotherapeutics Inc. Common Stock (IOVA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Iovance Biotherapeutics Inc. Common Stock — how do they compare? Icl Group Ltd trades at $5.02 (market cap $6.47B), while Iovance Biotherapeutics Inc. Common Stock trades at $14.8 (market cap $6.04B). The key difference: Icl Group Ltd and Iovance Biotherapeutics Inc. Common Stock are close in size by market cap, and Icl Group Ltd pays a 4.11% dividend while Iovance Biotherapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Iovance Biotherapeutics Inc. Common Stock for 0 Days on average.
| ICL | IOVA | |
|---|---|---|
Market Cap | $6.47B | $6.04B |
Volume | 1,387,140 | 14,805,993 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $14.82 |
52-Week Low | $4.80 | $1.81 |
Typical Hold Time | 56 Days | 0 Days |
Enterprise Value | $9.11B | $5.97B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no recent price movement. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported $7.15B revenue in 2025 with a 3.95% net margin, while valuation ratios appear reasonable with P/E of 20.83 and P/S of 0.84. Recent earnings showed Q2 2026 beat expectations with $0.12 EPS versus $0.11 expected. The company maintains stable cash flow generation despite recent net cash outflows.
ICL presents a cautious opportunity with 19.7% upside to the $6.08 consensus price target, though analyst sentiment is neutral with 100% hold ratings. Key risks include fertilizer industry headwinds from higher input costs and competitive pressures. The dividend yield of approximately 1.2% provides income support while investors await earnings recovery toward projected 2026 profitability improvement.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Iovance Biotherapeutics Inc. Common Stock
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →
